We believe that the technology that underpins the Ultrasonic Pain Relief device marks a significant advance in non-invasive therapeutic treatment for pain. As such, it has potential as a breakthrough treatment for tendonitis and other musculoskeletal injuries and disorders in which pain can be a debilitating factor.
To date, the technology has been tested on a very small scale in individuals suffering pain from chronic musculoskeletal disorders, including lateral epicondylitis (tennis elbow), De Quervain’s tenosynovitis (affecting tendons at the side of the wrist and base of the thumb), and plantar fascia inflammation, with encouraging results. In all cases, after a treatment of between 3 and 5 minutes using the Ultrasonic Pain Relief device on the affected area, significant pain reduction was evident within 24 hours, with lasting effects.
Planning is now underway to start clinical trials to confirm the effectiveness of this new Ultrasonic Pain Relief technology as a therapeutic treatment for the relief of pain in musculoskeletal disorders.
Preliminary work for a double-blind clinical trials involving a cohort of 40 individuals with tennis elbow is expected to start in October 2017, with the trial itself commencing in March 2018.
The clinical trials focuses on the management of common musculoskeletal conditions, spanning clinical epidemiology, outcomes research and the assessment of health technology.